Exclusive: ImmunoGen CEO Mark Enyedy shares views on product strategy

In an exclusive interview with the AlphaStreet, ImmunoGen Inc (NASDAQ: IMGN) executive chief Mark Enyedy spoke about the company's product strategy, pipeline, and more.

The pharma sector continues to be running on the tight budgets due to disruptive COVID-19 pandemic. However, ImmunoGen presented a different story when it reported Q1 earnings last week.

In a post-earnings interview, ImmunoGen CEO Mark Enyedy told AlphaStreet that the firm entered the lockdown phase with enough drug supply for all the existing clinical trial studies, including for Phase 3-level platinum-resistant ovarian cancer candidate mirvetuximab soravtansine as...

Please find the exclusive interview and the visual representation of the earnings in the link herewith